Special Issue

Application of Silver Nanoparticles in Cancer Treatment

Message from the Guest Editors

Despite the enormous progress made in recent years in terms of research and therapies, cancer continues to be one of the most insidious challenges of modern medicine. Features such as multidrug resistance, recurrence, migration, invasion, and the ability to evade the host's immune system are among the main causes that make the majority of conventional treatments ineffective. To deal with these problems, innovative therapeutic methods have been developed, such as immunotherapy, gene therapy, and the use of metal nanoparticles. Among metal nanoparticles, silver nanoparticles (SNs) are attracting a lot of interest thanks to their anticancer properties, the ability to enhance the efficacy of treatments such as radiotherapy or phototherapy, and the possibility of being used in combination with other nanoparticles. Furthermore, properties such as plasmon resonance make SNs interesting diagnostic tools.

This Special Issue aims to highlight and collect research articles and reviews focused on the use of silver nanoparticles for the treatment and diagnosis of cancer.

Guest Editors

Dr. Serena Mazzucchelli

Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milan, Italy

Dr. Francesco Ragonese

Department of Chemistry, Biology and Biotechnologies, University of Perugia, Via dell'Elce di Sotto 8, 06123 Perugia, Italy

Deadline for manuscript submissions

31 March 2026



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/201608

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

